Cognition Therapeutics to Participate in the 2022 Cantor Fitzgerald Neurology & Psychiatry Conference
September 29 2022 - 6:30AM
Cognition Therapeutics, Inc. (Nasdaq: CGTX) (the “Company” or
“Cognition”), a clinical-stage biopharmaceutical company engaged in
the discovery and development of innovative, small molecule
therapeutics targeting age-related degenerative diseases and
disorders of the central nervous system and retina, announced today
that the Company’s president and CEO, Lisa Ricciardi will
participate in a panel discussion and host one-on-one meetings at
the Cantor Fitzgerald Neurology & Psychiatry Conference
taking place in San Francisco from October 6-7, 2022.
Details of Cognition’s participation in the conference are as
follows:
Event: Cantor Fitzgerald Neurology &
Psychiatry Conference
Panel Title: Wave of Innovation for Alzheimer’s
Disease – Small & Large Molecule Approaches for a Diverse Set
of Targets
Panel Date/Time: October 7, 2022, from 9:00
a.m. – 10:00 a.m. PT
The panel presentation will be available only to conference
participants and no webcast will be available. To schedule a
meeting with Cognition’s management team during the conference,
please contact your Cantor representative.
About Cognition Therapeutics, Inc.Cognition
Therapeutics, Inc. is a clinical-stage biopharmaceutical company
engaged in the discovery and development of innovative, small
molecule therapeutics targeting age-related degenerative disorders
of the central nervous system and retina. We are currently
investigating our lead candidate CT1812 in clinical programs in
Alzheimer’s disease, dementia with Lewy bodies (DLB) and dry
age-related macular degeneration (dry AMD). We believe CT1812 and
our pipeline of σ-2 receptor modulators can regulate pathways that
are impaired in these diseases. We believe that targeting the σ-2
receptor with CT1812 represents a mechanism functionally distinct
from other current approaches in clinical development for the
treatment of degenerative diseases. More about Cognition
Therapeutics and its pipeline can be found
at https://cogrx.com.
Forward-Looking StatementsThis press release
contains forward-looking statements within the meaning of The
Private Securities Litigation Reform Act of 1995. All statements
contained in this press release, other than statements of
historical facts or statements that relate to present facts or
current conditions, including but not limited to, statements
regarding our cash and financial resources and our clinical
development plans, are forward-looking statements. These statements
involve known and unknown risks, uncertainties and other important
factors that may cause our actual results, performance, or
achievements to be materially different from any future results,
performance, or achievements expressed or implied by the
forward-looking statements. In some cases, you can identify
forward-looking statements by terms such as “may,” “might,” “will,”
“should,” “expect,” “plan,” “aim,” “seek,” “anticipate,” “could,”
“intend,” “target,” “project,” “contemplate,” “believe,”
“estimate,” “predict,” “forecast,” “potential” or “continue” or the
negative of these terms or other similar expressions. We have based
these forward-looking statements largely on our current
expectations and projections about future events and financial
trends that we believe may affect our business, financial
condition, and results of operations. These forward-looking
statements speak only as of the date of this press release and are
subject to a number of risks, uncertainties and assumptions, some
of which cannot be predicted or quantified and some of which are
beyond our control. Factors that may cause actual results to differ
materially from current expectations include, but are not limited
to: competition, our ability to secure new (and retain existing)
grant funding, our ability to grow and manage growth, maintain
relationships with suppliers and retain our management and key
employees; our ability to successfully advance our current and
future product candidates through development activities,
preclinical studies and clinical trials and costs related thereto;
the timing, scope and likelihood of regulatory filings and
approvals, including regulatory approval of our product candidates;
changes in applicable laws or regulations; the possibility that the
we may be adversely affected by other economic, business or
competitive factors; our estimates of expenses and profitability;
the evolution of the markets in which we compete; our ability to
implement our strategic initiatives and continue to innovate our
existing products; our ability to defend our intellectual property;
the impact of the COVID-19 pandemic on our business, supply chain
and labor force; and the risks and uncertainties described in the
“Risk Factors” section of our filings made with the Securities
Exchange Commission. You should not rely on these forward-looking
statements as predictions of future events. The events and
circumstances reflected in our forward-looking statements may not
be achieved or occur, and actual results could differ materially
from those projected in the forward-looking statements. Moreover,
we operate in a dynamic industry and economy. New risk factors and
uncertainties may emerge from time to time, and it is not possible
for management to predict all risk factors and uncertainties that
we may face. Except as required by applicable law, we do not plan
to publicly update or revise any forward-looking statements
contained herein, whether as a result of any new information,
future events, changed circumstances or otherwise.
Contact Information: Cognition
Therapeutics, Inc. info@cogrx.com
Aline Sherwood (media) Scienta
Communications asherwood@scientapr.com Daniel
Kontoh-Boateng/Rosalyn Christian (investors) Tiberend
Strategic Advisors, Inc.dboateng@tiberend.com
rchristian@tiberend.com
Cognition Therapeutics (NASDAQ:CGTX)
Historical Stock Chart
From Apr 2024 to May 2024
Cognition Therapeutics (NASDAQ:CGTX)
Historical Stock Chart
From May 2023 to May 2024